VAXCYTE INC (PCVX) Stock Price, Quote, News and Overview
NASDAQ:PCVX - Nasdaq - US92243G1085 - Common Stock - Currency: USD
PCVX Quote, Performance and Key Statistics
32.92
-1.59 (-4.61%)
The current stock price of PCVX is 32.92 USD. In the past month the price decreased by -53.48%. In the past year, price decreased by -45.78%.
PCVX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About PCVX
Company Profile
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 414 full-time employees. The company went IPO on 2020-06-12. The company is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Company Info
VAXCYTE INC
825 Industrial Road, Ste. 300
San Carlos CALIFORNIA 94404 US
CEO: Grant E. Pickering
Employees: 254
Company Website: https://vaxcyte.com/
Investor Relations: https://investors.vaxcyte.com/
Phone: 16508370111
VAXCYTE INC / PCVX FAQ
What is the stock price of VAXCYTE INC today?
The current stock price of PCVX is 32.92 USD. The price decreased by -4.61% in the last trading session.
What is the ticker symbol for VAXCYTE INC stock?
The exchange symbol of VAXCYTE INC is PCVX and it is listed on the Nasdaq exchange.
On which exchange is PCVX stock listed?
PCVX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VAXCYTE INC stock?
17 analysts have analysed PCVX and the average price target is 134.64 USD. This implies a price increase of 308.99% is expected in the next year compared to the current price of 32.92. Check the VAXCYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VAXCYTE INC worth?
VAXCYTE INC (PCVX) has a market capitalization of 4.24B USD. This makes PCVX a Mid Cap stock.
How many employees does VAXCYTE INC have?
VAXCYTE INC (PCVX) currently has 254 employees.
What are the support and resistance levels for VAXCYTE INC (PCVX) stock?
VAXCYTE INC (PCVX) has a resistance level at 34.52. Check the full technical report for a detailed analysis of PCVX support and resistance levels.
Should I buy VAXCYTE INC (PCVX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PCVX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PCVX, evaluating the profitability, health, valuation and growth aspects
- VAXCYTE INC (PCVX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VAXCYTE INC (PCVX) Sales and EPS estimates to see what analysts future expectations are.
- VAXCYTE INC (PCVX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VAXCYTE INC (PCVX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VAXCYTE INC (PCVX) Stock Chart to make your own analysis
- VAXCYTE INC (PCVX) Latest news and press-releases to stay up to date.
Does VAXCYTE INC (PCVX) stock pay dividends?
PCVX does not pay a dividend.
When does VAXCYTE INC (PCVX) report earnings?
VAXCYTE INC (PCVX) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of VAXCYTE INC (PCVX)?
VAXCYTE INC (PCVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.79).
What is the Short Interest ratio of VAXCYTE INC (PCVX) stock?
The outstanding short interest for VAXCYTE INC (PCVX) is 9.57% of its float. Check the ownership tab for more information on the PCVX short interest.
PCVX Technical Analysis
PCVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PCVX. PCVX has a great financial health rating, but its profitability evaluates not so good.
PCVX Financial Highlights
Over the last trailing twelve months PCVX reported a non-GAAP Earnings per Share(EPS) of -3.79. The EPS increased by 8.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.21% | ||
| ROE | -14.03% | ||
| Debt/Equity | 0 |
PCVX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to PCVX. The Buy consensus is the average rating of analysts ratings from 17 analysts.